Abstract P4-11-08: Comparative analysis of clinician and AI decision making in HR+/HER2- early breast cancer
Roberto Buonaiuto(Scuola Superiore Meridionale), Mario Giuliano(Regione Campania), Aldo Caltavituro(University of Naples Federico II), Pietro De Placido(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Grazia Arpino(University of Naples Federico II), Giampaolo Bianchini(Vita-Salute San Raffaele University), Valeria Forestieri(University of Naples Federico II), Rossana Di Rienzo(University of Naples Federico II), Alessandra Longobardi(Federico II University Hospital), Erica Pietroluongo(University of Naples Federico II), V. Cantile, Carmen Criscitiello(University of Milan), Federica P. Mangiacotti(Federico II University Hospital), Angela Grieco(University of Naples Federico II)
Cited by 1
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413